Pharmaphorum

Pharmaphorum.com stands out as a leading online platform dedicated to thought leadership in the pharmaceutical sector. It delivers daily news, opinions, and insights that empower industry leaders to navigate the wider healthcare environment. The content features regular input from fellow professionals, creative service providers, healthcare practitioners, payers, policymakers, patient groups, and patients themselves.

International, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#510422

United States

#304072

Health/Biotechnology and Pharmaceuticals

#288

Traffic sources

Monthly visitors

Articles

Changing Faces - Board of Directors and Advisory Boards - April 2025

1 week ago | pharmaphorum.com | Jonah Comstock

April was a busy month for Boards, with a number of biotechs appointing new Chairs, as well as plenty of other Board seat changes. Read on for the highlights. Patient-turned-entrepreneur takes helm on Adcendo Board. Laura Shawyer has been named Chair of the Board of Directors at Adcendo ApS, a clinical-stage biotechnology company developing antibody-drug conjugates (ADCs) targeting cancers with high unmet medical needs.
MSD and Daiichi Sankyo pull HER3-DXd's FDA filing

1 week ago | pharmaphorum.com | Phil Taylor

A year ago, MSD and Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) was rejected by the FDA, and the partners have now withdrawn a filing intended to get the programme back on track.
Just call it ‘good marketing’: Dan Gandor on why omnichannel matters

1 week ago | pharmaphorum.com | Jonah Comstock

Dan Gandor has spent his whole career pioneering digital techniques for pharma marketing and creating centres of excellence at pharma companies like Takeda and AbbVie. Last month, he joined pharmaphorum's parent company and pharma marketing agency EVERSANA as EVP and Head of Omnichannel and Digital Transformation. I caught up with Dan to find out why he made the leap from pharma to agency, why omnichannel marketing still matters, how he’s thinking about AI, and more.
Old COVID tweet lands Pfizer in new trouble with PMCPA

1 week ago | pharmaphorum.com | Phil Taylor

Pfizer has been found to be in breach of the UK pharma industry's code of practice with posts on Twitter (now X), dating back to 2020, that concerned its COVID-19 vaccine. The Prescription Medicines Code of Practice Authority (PMCPA) investigated a complaint raised by a member of the public over the tweets, which claimed that they promoted an unlicensed medicine and made misleading claims.
Moderna's $760m-plus flu vaccine contracts are nixed by HHS

1 week ago | pharmaphorum.com | Phil Taylor

News In January, Moderna was celebrating a $590 million contract with the US government to develop pandemic flu vaccines, one of the last actions by the Biden administration. Now – despite positive clinical results and an ongoing outbreak of bird flu in poultry and cattle in the US – the programme has been cancelled. The award from the Biomedical Advanced Research and Development Authority (BARDA), part of the US Department of Health and Human Services (HHS) now led by Robert F Kennedy Jr,...
Data sets up filing of new GSK antibiotic this year

1 week ago | pharmaphorum.com | Phil Taylor

In a second piece of good news in the development of new antimicrobials this week, GSK has said it will file its oral carbapenem antibiotic tebipenem HBr for approval before the end of this year after a pivotal study was stopped early.
Eisai says patent win blocks Lenvima generic to 2036

1 week ago | pharmaphorum.com | Phil Taylor

Eisai has won a patent infringement lawsuit brought against Shilpa Medicare that sought to prevent the Indian generic drugmaker from launching a version of its MSD-partnered cancer drug Lenvima in the US. The verdict of the US district court in New Jersey is that Shilpa's generic infringes a US patent on multikinase inhibitor Lenvima (lenvatinib), namely No. 11,186,547, which covers pure forms of lenvatinib mesylate.
InflaRx stock halves after it drops lead drug

1 week ago | pharmaphorum.com | Phil Taylor

News InflaRx has taken the difficult decision to abandon its drug development programme, vilobelimab for rare inflammatory skin disorder pyoderma gangrenosum (PG), a move that has pummelled its share price. The Germany-based but Nasdaq-listed biotech said that, after reviewing data from the first 30 patients enrolled in its phase 3 trial of anti-complement C5a monoclonal antibody vilobelimab in PG, its expert advisors had advised it to discontinue the study. Based on a futility analysis,...
FDA fast-tracks Teva's coeliac disease treatment

1 week ago | pharmaphorum.com | Phil Taylor

News The only available treatment for a patient with coeliac disease is a strict gluten-free diet, which is often not enough on its own to curb symptoms. Now, the FDA has said it will carry out a speedy review of a Teva medicine that it hopes can change that. The US regulator has awarded fast-track status for TEV-53408, an anti-IL-15 antibody currently in a phase 2a trial as an add-on to a restricted diet for the disorder, which could lead to a more rapid review and allow it to be brought to...
Manufacturing issues scupper Savara's lead drug filing

1 week ago | pharmaphorum.com | Phil Taylor

The FDA has refused to accept a filing from Savara for Molbreevi, a drug developed for a rare respiratory disease, and asked for more manufacturing and quality control data. Molbreevi – a new inhaled formulation of the well-established and off-patent white blood cell stimulator molgramostim – is Philadelphia-based Savara's lead drug and had been filed as a therapy for autoimmune pulmonary alveolar proteinosis (PAP).